Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib

Basit Öğe Kaydı
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.contributor.authorErdogan, Bulent
dc.contributor.authorOzcan, Erkan
dc.contributor.authorGokmen, Ivo
dc.contributor.authorGokyer, Ali
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorKostek, Osman
dc.contributor.authorHacioglu, Muhammet Bekir
dc.date.accessioned2024-06-12T10:59:40Z
dc.date.available2024-06-12T10:59:40Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractAim: In this study, we aimed to analyze the effect of prognostic nutritional index and neutrophile lymphocyte ratio on the overall survival (OS) in patients treated with regorafenib. Materials and Methods: Metastatic colorectal cancer (CRC) patients who treated with regorafenib between 2016 and 2020 in a single center were evaluated retrospectively. ROC analysis was used for neutrophile lymphocyte ratio (NLR's) and prognostic nutritional index (PNI's) optimum cut-off value. The relationship between OS with PNI and NLR was investigated. Results: Fifty-two patient's data were analyzed. The median age was 57 years, 22 (41.5%) of the patients were female. The optimal cut-off value of PNI for OS was 45.7 according to ROC curve analysis. The median NLR value was accepted as 2.7. Median OS was 8.3 months. Patients who have high PNI value than 45.7 had longer OS (12.09 months vs. 6.31 months hazard ratio [HR]: 0.37 95% confidence interval [CI]: 0.19-0.73 P = 0.003) and there was a tendency for longer OS with low NLR value then median (12.05 months vs. 6.14 months HR: 0.54 95% CI: 0.29-1.23 P = 0.057). Primary tumor resected patients had longer OS than nonresected patients (12.05 months vs. 6.30 months HR: 0.34 95% CI: 0.17-0.66 P = 0.001). In multivariate analysis, high PNI value more than 45.7 (HR: 0.40 95% CI: 0.18-0.88 P = 0.02) and resection of the primary tumor (HR: 0.40 95% CI: 0.21-0.80 P = 0.01) were the only independent factors for longer OS. Conclusion: Metastatic CRC patients with high pretreatment PNI and primary tumor resected are more likely to have longer OS with regorafenib. PNI is more reliable index than NLR to predict OS in metastatic CRC patients treated with regorafenib.en_US
dc.identifier.doi10.4103/jcrt.jcrt_1620_21
dc.identifier.endpage767en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue3en_US
dc.identifier.pmid37470607en_US
dc.identifier.scopus2-s2.0-85165353728en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage762en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.jcrt_1620_21
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20528
dc.identifier.volume19en_US
dc.identifier.wosWOS:001062420500039en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDisease Controlen_US
dc.subjectNeutrophil-Lymphocyte Ratioen_US
dc.subjectPrognostic Nutritional Indexen_US
dc.subjectBevacizumaben_US
dc.subjectCetuximaben_US
dc.subjectPlusen_US
dc.titleRelationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafeniben_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu